A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
User shared 13 months of progress using finasteride, microneedling, vitamins, and scalp care, and recently started stemoxydine. The post includes before and after photos.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.
The user experienced rapid hair thinning on top of the head after two GFC treatments, despite using topical minoxidil for four years. Hair on the sides and back became thicker, leading to confusion and questioning of the treatment decision.
RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.
The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.
The conversation discusses whether stemoxydine needs to be used for life for hair loss treatment. One user suggests that stemoxydine does not require lifelong use and can make hair exit the resting phase faster, but the benefits may be temporary.
The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.
Minoxidil may inhibit collagen synthesis at high concentrations, with anecdotal reports of skin aging but limited research. Dermatologists and other specialists show little interest in studying minoxidil's side effects.
Hair is growing faster after 2 weeks of using topical vitamin D3 in alcohol/oil. The user plans to continue the experiment for 3 months before giving a full review.
The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.
The conversation discusses making a RU58841 solution for hair loss prevention and includes personal experiences with using RU58841 and minoxidil for hair regrowth, with a mention of monitoring health effects.
The conclusion of the conversation is that the user, DixonYasz, has been using Hims spray (which contains both finasteride and minoxidil) for 4 months and is happy with the results. They have noticed their thinning spots filling in with color and their scalp being less visible. They also mentioned using a dermaroller once a week.
A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.
Treatments for hair loss, such as minoxidil, finasteride, and RU58841; humorous posts about hair loss; and the choice to stop using treatments in exchange for a different look.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
A user noticing changes in the L'Oreal Serioxyl hair treatment, including a different smell, mismatched batch numbers, and a color change. They question if it's a new formula and seek alternatives to stemoxydine. Another user questions if the positive results were due to stemoxydine or other medications.
The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.
Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.
A user shared an 8-month update on hair regrowth using HIMS fin/min spray and dermastamping every two weeks, showing significant improvement. Others commented on their own progress and hopes for similar results.
User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
The user is using a topical solution with finasteride, minoxidil, and tretinoin and is considering adding GHK-Cu to enhance hair growth and quality. Another user suggests diluting GHK-Cu and storing it in a smaller, refrigerated bottle.
The user shared two-month results using a topical spray with 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin, showing improvement in hair loss. The user also mentioned using hair fibers previously and dermastamping inconsistently.